Regorafenib in Metastatic Colorectal Cancer: An Exploratory Biomarker Study
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 15 Nov 2017 Status changed from active, no longer recruiting to discontinued.
- 30 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Mar 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2018.